Data as of Dec 19
| -0.25 / -4.42%|
The 2 analysts offering 12-month price forecasts for Oramed Pharmaceuticals Inc have a median target of 28.50, with a high estimate of 30.00 and a low estimate of 27.00. The median estimate represents a +426.80% increase from the last price of 5.41.
The current consensus among 2 polled investment analysts is to Buy stock in Oramed Pharmaceuticals Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.